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DMSO/glycerol	improved	the	ability	to	observe	biological	activity	(i.e.	reduced	MIC	
values)	for	4	(2,	4,	5,	6)	out	the	7	active	compounds.
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CHAPTER	III	
	
EXPERIMENTAL	
	
	
3.1	Standard	Preparation		
	 Standards	were	ordered	from	from	Sigma	Aldrich	(3,	7,	8,	9,	10,	11,	12,	13,	
16,	17,	18,	19,	20,	21),	Selleckchem	(1,	2,	4,	5,	6),	Acros‐organics	(14),	Bioviotica	
(15)	and	were	suspended	to	10	mM	using	either	50/50	(v/v)	DMSO/glycerol	(Fisher	
Scientific)	or	DMSO/nanopure	water	in	vials.	A	timer	was	then	started	and	the	
standards	were	vortexed	first	to	see	if	the	compound	would	easily	dissolve.	In	the	
event	of	poor	solubility,	the	compounds	were	placed	in	sonicator	to	break	up	
clumps,	then	a	hot	water	bath	for	a	short	period	and	vortexed	again.	After	
solubilizing	to	the	best	of	our	ability,	serial	2‐fold	dilutions	were	performed	from	10	
mM	to	0.78	µM	for	each	standard.	
3.2	Antimicrobial	Testing	 	
	 Overnight	seed	cultures	were	diluted	1:3	with	Müeller‐Hinton	broth	and	
shaken	for	2	hours	at	300	rpm.	An	additional	dilution	to	normalize	the	colony	
forming	units	(CFU)	for	each	plate	was	performed	to	give	a	final	dilution	of	1.0	x	105	
CFU/ml	based	on	OD600	of	0.118	S.	aureus	after	the	2	hours	of	shaking.	Evaluation	of	
antimicrobial	testing	was	performed	utilizing	a	96‐well	sample	plate	setup	in	which	
10	uL	of	each	compound	was	transferred	into	a	well	containing	190	uL	of	broth	and	
23 
 
50	uL	of	bacteria	(SA1199	Staphylococcus	aureus).	Final	concentrations	of	
compound	ranged	from	400	µM	to	3µM	in	triplicate.	The	plates	were	then	shaken	at	
1000	rpm	at	37	˚C	in	a	Stuart	S1505	microtitre	plate	shaker	for	at	least	18	hours.	
Following	incubation,	plates	were	read	using	a	Synergy	H1	Mutli‐Mode	Reader	at	
600	nm	to	obtain	absorption	spectra.	A	blank	plate’s	optical	density	readings	
containing	no	bacteria	(240	uL	broth	and	10	uL	compound)	was	then	subtracted	
from	the	sample	plate	to	give	the	OD600	of	the	bacteria	alone.		
3.3	Solubility	Analysis	
	 Using	the	blank	plate,	solubility	of	each	well	concentration	(400µM	to	3µM)	
was	evaluated	by	subtracting	out	the	absorbance	values	of	a	2%	DMSO/glycerol	or	
2%	DMSO/water	control	to	find	the	absorbance	value	of	the	compound	in	question.	
These	OD600	values	were	then	plotted	against	concentration	for	comparison	of	
solvents.	The	blank	plate	was	also	analyzed	at	400	µM	across	multiple	wavelengths	
from	280	nm	to	800	nm	to	determine	if	there	was	an	observable	absorbance	peak	
near	the	600	nm	range.	The	400	µM	wells	were	then	vacuum	filtered	and	analyzed	
via	LC‐MS	(CH3CN/H2O	(with	0.1%	formic	acid)	15‐100%	CH3CN	over	10	minutes)	
using	a	Q	Exactive	Plus	Hybrid	Quadropole‐Orbitrap	coupled	to	an	Acuity	ultra‐high	
performance	liquid	chromatography	(UPLC)	system.	Selected	ion	chromatograms	
for	each	compound	were	then	compared.
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CHAPTER	IV	
	
CONCLUSION	
	
	
In	conclusion,	this	project	was	developed	in	order	to	quickly	assess	
compound	solubility	within	our	bioassays	as	well	as	improve	solubility	with	trouble	
compounds	with	the	addition	of	glycerol	as	a	co‐solvent.	Our	studies	found	glycerol	
was	suitable	co‐solvent	with	DMSO	for	improving	solubility	in	bioassay	screenings	
of	S.	aureus.		It	also	found	of	the	21	compounds	tested,	10	which	showed	
improvement	in	the	time	it	took	to	solubilize,	6	showed	solubility	enhancements	in	
bioassays,	and	4	showed	improvements	in	MICs.	These	findings	show	we	now	have	
a	rapid	way	to	assess	our	solubility	and	offer	a	novel	solution	to	solubility	problems	
which	may	arise.
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